Carbenicillin disodium destined for sterile injectable dosage forms in companion animal medicine is manufactured under the same aseptic core constraints as other beta-lactam parenterals, but its thermal lability and pH-dependent degradation kinetics create a narrower processing window than amoxicillin or ampicillin sodium. The API powder is filled as a sterile lyophilized cake into Type I borosilicate glass vials after aseptic filtration of a bulk solution held at 10–15 °C; terminal steam sterilization is avoided because the beta-lactam ring undergoes hydrolysis above 25 °C and in saturated steam the degradation to penicilloic acid exceeds acceptable limits within minutes. All open handling takes place in ISO 14644-1 Class 5 laminar-airflow zones inside a Grade B background, with viable and non-viable particle monitoring per EU GMP Annex 1. Compliance for the injectable grade is anchored to the current USP monograph for Carbenicillin Disodium for Injection, sterility testing per USP <71>, bacterial endotoxin testing per USP <85> with a limit not exceeding 0.05 EU/mg for parenteral veterinary products, particulate matter limits per USP <788> for small-volume injections, elemental impurities under ICH Q3D, and residual solvents under ICH Q3C.

The sterile powder is typically presented as a single-active lyophile: each 20 mL vial contains carbenicillin disodium equivalent to 1 g or 5 g carbenicillin free acid. The formulation ratio is effectively 100% active on a dry solids basis when no buffer is used; where pH adjustment is required, dibasic sodium phosphate is incorporated at 2.0–3.0% w/w of the dry cake to maintain reconstituted pH between 6.0 and 7.0. Because carbenicillin disodium is freely soluble, the bulk solution is prepared at 250–400 mg/mL active free acid. The solution is filtered through a 0.22 μm PVDF membrane and filled into depyrogenated vials before lyophilization. The freeze-drying cycle typically includes freezing at −40 °C, primary drying at −20 °C to +10 °C with chamber pressure 80–150 μbar, and secondary drying at 30 °C for 6–10 h until residual moisture is below 1.0%.

On production-scale lyophilizers, the fill line must maintain a low bioburden before sterile filtration below 10 CFU/100 mL; prefiltration pressure differentials are held below 0.8 bar to avoid filter bypass and beta-lactam particle shedding. Stoppering occurs under vacuum or partial nitrogen to limit oxidative degradation. Vial headspace oxygen is commonly kept below 2.0%. Reconstituted solutions for intravenous or intramuscular administration are prepared at the point of use with Water for Injection or 0.9% sodium chloride to a final concentration of 250 mg/mL; the resulting solution is used within 24 h at 2–8 °C because hydrolysis in aqueous media follows first-order kinetics and unacceptable degradation can occur beyond this hold time. Published data for exact commercial lyophilization cycle parameters is limited; vial thermocouple mapping and freeze-drying microscopy are required to establish cake collapse temperatures for each specific API lot. The sterile powder is filled into 1 g and 5 g vials as the terminal finished product type.

What Prevents Gastric Decomposition of Carbenicillin in Oral Tablet Dosage Forms?

Oral tablets for companion animal use require the indanyl sodium ester of carbenicillin rather than the disodium salt. The ester is relatively stable in gastric fluid and is hydrolyzed by intestinal esterases to release free carbenicillin after absorption. Tablet formulation therefore focuses on protecting the prodrug from moisture during granulation while ensuring complete dissolution in the upper intestine. Compliance anchors include USP <701> disintegration, USP <711> dissolution testing in 0.1 N HCl for the first 30 min followed by pH 6.8 phosphate buffer for 45 min, and ICH Q3D elemental impurities. Because carbenicillin indanyl sodium is hygroscopic, the manufacturing suite is maintained at ≤ 40% RH and 18–22 °C; tablets are blister-packed with aluminum foil to limit moisture ingress.

Each film-coated tablet is compressed to deliver 382 mg carbenicillin free acid, equivalent to 516 mg carbenicillin indanyl sodium per unit based on a molecular weight conversion factor of 1.36. A direct compression or roller-compacted granulation may be used. The active component typically represents 45–55% w/w of the core tablet; microcrystalline cellulose and lactose monohydrate together contribute 25–35% w/w; crospovidone is included at 4–6% w/w as disintegrant; magnesium stearate at 0.5–1.0% w/w; and an HPMC-based film coat at 2–3% w/w of core weight masks the bitter aftertaste. Actual ratios require verification by formulation development because published data for veterinary-specific carbenicillin tablet formulations is limited.

Roller compaction is preferred over wet granulation to avoid exposing the moisture-sensitive prodrug to aqueous binders. The blend is compacted at roller pressure 4–6 kN/cm, granulated through a 1.0 mm screen, and compressed on a rotary tablet press at 15–25 rpm. Tablet hardness is maintained between 10 kp and 15 kp, with friability below 1.0% to survive film-coating pan stress. Dissolution acceptance is Q = 80% at 60 min in pH 6.8 buffer; tablets failing this threshold indicate insufficient disintegration or ester hydrolysis. Film-coated oral tablets in 382 mg free-acid equivalent strength are the terminal dosage form.

Enteric-Coated Bead Capsules: Fluid-Bed Parameters for Carbenicillin Sodium

Hard gelatin capsules containing carbenicillin sodium present a different challenge: the disodium salt is acid-labile and will be inactivated in the stomach if the capsule releases unprotected drug. The manufacturing route applies a drug layer and an enteric polymer coating to inert microcrystalline cellulose spheres in a Wurster fluid-bed column. Compliance is established by USP <711> dissolution testing with 2 h in 0.1 N HCl followed by 45 min in pH 6.8 phosphate buffer; enteric performance is considered acceptable where not more than 10% of the labeled active is released in acid and not less than 75% is released in buffer. Additional specifications include USP <701> disintegration for capsules and ICH Q3D elemental impurities.

The drug layering dispersion contains carbenicillin sodium at 20–30% w/w of the liquid dispersion, with 5–8% w/w povidone K30 as binder and 1–2% w/w talc as anti-tack agent. The target drug load on the spheres is 50–65% w/w of the total bead mass. Enteric coating comprises methacrylic acid copolymer dispersion 15–20% w/w dry polymer weight relative to core bead weight, triethyl citrate at 10% of polymer solids as plasticizer, and talc at 40–50% of polymer solids to prevent bead agglomeration during spraying. Finished capsules are filled to deliver 250 mg or 500 mg carbenicillin free acid per capsule.

Processing conditions in the Wurster column are constrained by the heat sensitivity of the beta-lactam ring: inlet air temperature is maintained at 40–50 °C, product temperature at 28–32 °C, and spray rate at 4–8 g/min/kg of bead charge. The enteric polymer is sprayed using an inner nozzle diameter of 0.8 mm with atomizing air pressure 1.5–2.0 bar. After coating, beads are cured at 45 °C for 1 h to complete film coalescence. Residual moisture in the bead bed is held below 2.0% before encapsulation to prevent gelatin cross-linking and beta-lactam hydrolysis. Capsule filling on a dosator or tamping-pin machine is run at 60–80% of maximum speed to reduce bead fracture; acceptable bead attrition is below 5%. The resulting hard gelatin capsules, filled to 250 mg or 500 mg free acid, are the terminal dosage form.

For oral suspension granules, carbenicillin sodium is processed as a dry, free-flowing mixture that is reconstituted at the point of dispensing. The granules must redisperse within 30 s under manual shaking and deliver a stable suspension for 7 days at 2–8 °C; this differentiates the material from a simple powder blend because the suspending agent must be pre-hydrated without exposing the active to excessive moisture or heat. Non-sterile commercial granules for oral solution are controlled under USP <795> principles for extemporaneous preparation when produced in small batches; at industrial scale, 21 CFR Part 211 current good manufacturing practice applies. Microbial limits are tested per USP <61> and USP <62>; total aerobic microbial count is held below 10³ CFU/g and bile-tolerant Gram-negative bacteria are absent. Residual solvents from wet granulation are controlled under ICH Q3C.

The dry granule formulation contains carbenicillin sodium equivalent to 25 mg/mL or 50 mg/mL free acid after reconstitution. On a dry weight basis, the active ingredient is incorporated at 20–35% w/w; sucrose or sorbitol at 50–60% w/w as sweetener and bulking agent; sodium citrate and citric acid at 5–8% w/w to buffer the reconstituted vehicle between pH 5.5 and 6.5; xanthan gum at 1–2% w/w as suspending agent; and colloidal silicon dioxide at 0.5–1.0% w/w as glidant.

Wet granulation is performed in a low-shear planetary mixer using an isopropanol-water binder solution; the liquid addition rate is set so that the final granulation moisture does not exceed 3.0% before drying. The wet mass is passed through a 1.2 mm screen and dried in a fluid-bed dryer at inlet air temperature 35–40 °C until loss on drying is below 1.5%. Dried granules are milled through a 0.8 mm screen and filled into 100 mL or 150 mL amber glass bottles with a desiccant canister. Reconstitution instructions require adding potable water to the marked fill line and shaking for 30 s; the yielded suspension is stored at 2–8 °C and used within 7 days. The final presentation is granules for oral suspension in 100 mL or 150 mL amber glass bottles, reconstituted to 250 mg/5 mL or 500 mg/5 mL.

When a Non-Sterile API Premix Is Compounded for Extemporaneous Veterinary Use

In the extemporaneous compounding pathway, veterinary teaching hospitals and compounding pharmacies may use a bulk API premix to prepare patient-specific capsules, oral suspensions, or paste formulations when a registered finished product is unavailable or unsuitable for the species. The API is supplied as a trituration with a compatible diluent rather than as a pure powder because the neat API has low bulk density and is difficult to weigh accurately for small patients. A 1:10 or 1:100 w/w trituration with lactose monohydrate is typical. The diluent is pre-dried at 105 °C to constant weight before blending because residual moisture accelerates beta-lactam hydrolysis; the API-diluent blend is passed through a 250 μm screen to break agglomerates and then blended in a low-shear tumble mixer at 25 rpm for 15 min with vessel fill not exceeding 70% of total capacity.

Compliance for this non-sterile compounding path follows USP <795> for nonsterile preparations, USP <800> for hazardous drug handling where beta-lactam sensitization risk is classified as an occupational exposure concern, and FDA 21 CFR 211 if the premix is manufactured under registered drug establishment conditions. Potency uniformity is verified by sampling at least 10 locations across the blender and analyzing via HPLC with UV detection at 254 nm; acceptance is 90.0–110.0% of label claim for each sample, with relative standard deviation not exceeding 5.0%.

The blended premix is packaged in double polyethylene bags inside fiber drums with desiccant; headspace oxygen is reduced below 2.0% by nitrogen flushing. Compounded preparations from the premix are assigned beyond-use dates not exceeding 14 days for aqueous oral liquids at 2–8 °C and 180 days for intact capsules stored at 20–25 °C, unless site-specific stability data support longer dating. The premix itself is not a final patient dosage form; it is converted into capsules, oral suspensions, and pastes at the point of care for non-food companion animals.

Low-pH Bulk Solution Handling and Aseptic Filling Limits

Because carbenicillin sodium solutions degrade rapidly below pH 5.0, ready-to-use carbenicillin sodium injection solution is manufactured only where cold-chain distribution and short shelf life are acceptable. The solution is filled into Type I glass ampoules or cyclic olefin copolymer bags under aseptic conditions at a concentration of 250 mg/mL free acid. The bulk solution is buffered with 0.1 M citrate or phosphate buffer to pH 6.5–7.0; published product labels routinely require refrigerated storage and short use periods because the beta-lactam ring hydrolyzes far faster below pH 5.0 than at neutral pH.

The solution grade is controlled under USP <71> sterility, USP <85> endotoxins, USP <788> particulate matter, and Ph. Eur. 2.2.3 pH. The container closure system is tested under USP <661.1> for plastic components and USP <381> for elastomeric closures.

Manufacturing uses a closed, steam-in-place mixing vessel with a bottom-mounted magnetic stirrer operating at 100–150 rpm; the dissolution medium is Water for Injection cooled to 10–15 °C. The API is added under nitrogen overlay, and the solution is filtered through a 0.22 μm PVDF filter followed by a 0.1 μm absolute filter for bioburden reduction. Filling is performed on a peristaltic pump line at 50–100 vials/min for 10 mL or 20 mL presentations. Blow-fill-seal technology may be used for plastic ampoules, but equipment selection must be validated because published data on carbenicillin sodium heat degradation in blow-fill-seal extrusion is limited. Ready-to-use solution ampoules or bags of 10 mL and 20 mL are the terminal presentations.